Characterization of an interplay between a Mycobacterium tuberculosis MazF homolog, Rv1495 and its sole DNA topoisomerase I by Huang, Feng & He, Zheng-Guo
Characterization of an interplay between a
Mycobacteriumtuberculosis MazF homolog,
Rv1495 and its sole DNA topoisomerase I
Feng Huang and Zheng-Guo He*
National Key Laboratory of Agricultural Microbiology, Center for Proteomics Research, College of Life Science
and Technology, Huazhong Agricultural University, Wuhan 430070, China
Received May 5, 2010; Revised July 26, 2010; Accepted August 4, 2010
ABSTRACT
The MazEF systems are thought to contribute to the
capacity for long-term dormancy observed in the
human pathogen, Mycobacterium tuberculosis.
However, except for their functions as mRNA
interferases, little is known regarding any additional
cellular functions of these systems in the pathogen.
In the present study, we observed a negative inter-
play between MazF protein Rv1495 and the sole M.
tuberculosis DNA topoisomerase I (MtbTopA) with
respect to protein functions. Through its C-terminal
domain, MtbTopA physically interacted with and in-
hibited the mRNA cleavage activity of Rv1495.
Rv1495, in turn, inhibited the DNA cleavage activity
of MtbTopA as well as its function of relaxation of
supercoiled DNA. An N-terminus fragment of
Rv1495, designated Rv1495-N(29-56), lost mRNA
cleavage activity, but retained a significant physical
interaction and inhibitory effect on TopA proteins
from both M. tuberculosis and M. smegmatis. This
fragment, although less effective than the full-length
protein, was able to inhibit mycobacterial growth
when expressed through a recombinant plasmid in
M. smegmatis. The Rv1495 physically interacted with
the M. smegmatis TopA both in vitro and in vivo. Our
findings imply that MazEF systems can affect
bacterial survival by a novel mechanism that
allows direct modulation of M. tuberculosis
topoisomerase I.
INTRODUCTION
Toxin–antitoxin (TA) gene cassettes are widely found in
many free-living prokaryotes including a number of
pathogenic bacteria such as Mycobacterium tuberculosis
(1,2). These gene cassettes appear to be involved in bac-
terial survival as well as in the formation of persistent
pathogenic infections in hostile host-cell environments
(3). In a typical TA system, the toxin gene is usually
co-expressed with its cognate antitoxin gene present in
the same operon (4,5). The Escherichia coli chromosome,
for example, contains six such operons, two of which [the
relBE (6) and the mazEF (1) systems] have been most ex-
tensively studied (5). The mazEF system consists of two
adjacent genes, mazE and mazF, and has the properties
required for an addiction module. MazF is stable and
toxic, whereas MazE is a labile and antitoxic protein (1).
MazE and MazF interact with each other to form a
complex, MazE–MazF, which negatively regulates the ex-
pression of mazEF (7–9). Several recent studies have
revealed MazF to be a sequence-speciﬁc endoribonuclease
that recognizes speciﬁc cleavage sites within single-strand
RNA. For this reason, it has been termed an mRNA
interferase (8,10,11).
Mycobacterium tuberculosis is one of the most
devastating human pathogens, causing the deaths of
about two million people each year around the globe.
As it infects, this pathogen confronts a particularly
hostile host cell environment, including a restricted
access to nutrients and a reduced oxygen tension within
the host macrophage cells (12–14). The presence of TA
systems in M. tuberculosis may contribute to its ability to
undergo long term dormancy within these inhospitable
human tissues, and consequently might prove to be
essential for the persistence of the pathogen (3). This
potential importance of TA systems in the life cycle of
M. tuberculosis is suggested by the presence of a remark-
ably large number of these TA genes in its genome (15).
Of the nine MazF homologs discovered thus far in M.
tuberculosis (2,3,10,16), four have been shown to cause
cell growth arrest when induced in E. coli. The bacterial
MazF also shows an mRNA interferase activity
both in vivo and in vitro (3,10,16). However, except for
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cellular effects of the other numerous toxins in this
pathogen.
In contrast to its large number of TA genes, the genome
of M. tuberculosis encodes only one single topoisomerase I
(MtbTopA) (15). A related but nonpathogenic organism,
M. smegmatis, also possesses a single TopA-homolog
(MsmTopA) (17) that features a conserved N-terminal
domain (NTD) and a highly variable C-terminal domain
(CTD) (18). The MtbTopA topoisomerase might be essen-
tial for preventing hypernegative supercoiling of DNA
during transcription (19), and may also be involved in
pathogen survival as attempts to isolate transposon inser-
tion mutants in the topA gene have thus far been unsuc-
cessful (20). Although both the MazEF system and DNA
topoisomerase I appear to function in bacterial stress re-
sponses (3,20), interaction between these two proteins
remains to be characterized.
Recently, the M. tuberculosis MazF homolog, Rv1495,
was characterized as a toxin with ribonuclease activity
(3,10). In the current study, we report on an interplay
between Rv1495 proteins and DNA topoisomerase I
that results in mutual inhibition of their activities. An
N-terminus fragment of Rv1495, Rv1495-N(29-56),
loses its mRNA cleavage activity but retains its ability
to physically interact with and inhibit TopA from both
M. tuberculosis and M. smegmatis. The Rv1495-N(29-56)
fragment is further shown to inhibit mycobacterial
growth. These ﬁndings suggest a new mechanism that
allows the pathogenic MazEF systems of M. tuberculosis
to participate in modulating the activities of DNA topo-
isomerase I.
MATERIALS AND METHODS
DNA primers and peptides
All DNA primers for polymerase chain reactions
(PCR) were synthesized by Invitrogen and are listed in
Supplementary Table S1. Two short peptides Rv1495-
N28: MNAPLRGQ VYRCDLGYGAKPWL IVSNNA,
and Rv1495-N(29-56): RNRHTADVVAVRLTTTRRT
IPTWVAMGP were synthesized by GL Biochem
(Shanghai) Ltd.
Bacterial strains, plasmids, enzymes and chemicals
The host strain E. coli BL21 and pET28a vector
(Novagen) were used to express M. tuberculosis proteins.
The plasmids pBT, pTRG and E. coli reporter strains for
the bacterial two-hybrid assays were purchased from
Stratagene. pBluescript and pGEX-4T-1 were purchased
from Pharmacia. Restriction enzymes, T4 DNA ligase,
DNA polymerase, modiﬁcation enzymes, deoxynucleoside
triphosphates (dNTPs) and all antibiotics were purchased
from TaKaRa Biotech. DNA puriﬁcation kits were
purchased from Watson Biotechnologies. All plasmids
constructed in this study are listed in Supplementary
Table S2.
Cloning, expression and puriﬁcation of
M. tuberculosis proteins
Rv1495 and the topoisomerase I gene from M. tuberculosis
or M. smegmatis genome were ampliﬁed using their PCR
primers (Supplementary Table S1) and cloned into the
prokaryotic expression vector pET28a or pGEX-4T-1.
Escherichia coli BL21 (Novagen) was used as the host
strain to express and puriﬁed the proteins according to
our previously published procedures (21–23). Both 6  his
taggedandGST-fusedrecombinantproteinswereprepared
for activity andprotein–protein interaction assays. Puriﬁed
proteins were >95% pure as determined by SDS–PAGE
and subsequent staining by Coomassie blue. Protein
concentrations were determined by spectrophotometric
absorbance at 260nm according to Gill and von
Hippel (24).
Bacterial two-hybrid assay
The BacterioMatch II Two-Hybrid System Library
Construction Kit (Stratagene) was used to detect
protein–protein interactions between Rv1495 and topo-
isomerase I proteins. Bacterial two-hybrid system detects
protein–protein interactions based on transcriptional
activation and analysis was carried out according to pre-
viously published procedures (21–23). Positive growth
cotransformants were selected on the Selective Screening
Medium plate containing 5mM 3-amino-1,2,4-triazole
(3-AT) (Stratagene), 8mg/ml streptomycin, 15mg/ml
tetracycline, 34mg/ml chloramphenicol and 50mg/ml
kanamycin. Cotransformants containing pBT-LGF2 and
pTRG-Gal11
P (Stratagene) were used as positive controls
for an expected growth on the Screening Medium.
Cotransformants containing empty vector pBT and
pTRG were used as negative controls.
DNA relaxation assay
The assay was carried out according to the previously
published procedure (25,26). The supercoiled pBluescript
was incubated in the presence of mycobacterial topoisom-
erase I (0–0.15mM) with or without various amounts
of Rv1495 or its mutant proteins, and incubated at 37 C
for 40min. After incubation, proteinase K (1mg/ml)
and its buffer (100mM Tris–HCl, pH 7.8, 5mM EDTA,
0.5% SDS) were added to the mixture and were further
co-incubated for 15min at 37 C. Samples were resolved by
0.9% agarose gel electrophoresis and then stained with
ethidium bromide for analysis. Each analysis was per-
formed at least in triplicate and a representative set of
data was presented.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was carried
out to analyze single-stranded DNA-binding activity of
MtbTopA, as described earlier (27). 50-end-labeled
32-mer oligonucleotide (50-CAGTGAGCGAGCTTCCG
CTTGACATCCC AATA-30) (27) was used as a speciﬁc
single-stranded DNA substrate. The reaction mixtures
containing 40mM Tris–HCl (pH 8.0), 20mM NaCl,
1mM EDTA, 150nM oligonucleotide were incubated
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Rv1495(240–960nM) for 40min on ice. Rv0054
(single-stranded DNA-binding protein) was used as a
positive control. The protein–DNA complexes were
resolved on 6% non-denaturing PAGE (39.5:0.5) using
0.5  TBE (Tris–borate–EDTA) as the running buffer.
Gels were exposed to a storage-phosphor screen overnight
at room temperature. The images were acquired by a
Typhoon Scanner (GE healthcare). EMSA with plasmid
pBluescript DNA was carried out to analyze the
DNA-binding activity of Rv1495. The reactions contained
40mM Tris–HCl (pH 8.0), 20mM NaCl, 1mM EDTA
and 1.5–6mM protein. Reactions were performed on ice
for 30min. Samples were resolved by 0.8% TBE agarose
gel electrophoresis and then stained with ethidium
bromide for analysis.
Oligonucleotide cleavage assay
The assays for the single-stranded DNA-binding cleavage
activity of MtbTopA were performed as described earlier
(27). Varying concentrations of MtbTopA (100–400nM)
were co-incubated at 37 C for 30min with 200nM 32-mer
oligonucleotide, in the same buffer used for EMSA to
yield a 50-end-labeled 19-mer cleaved product. The
effects of Rv1495 on the cleavage activity of MtbTopA
(0.2mM) were analyzed using varying concentrations of
Rv1495 (3–9mM). Heat-denatured Rv1495 and GST
proteins were used as negative controls. The reactions
were stopped by adding 10ml loading buffer (95%
formamide, 20mM EDTA, 0.05% bromphenol blue and
0.05% xylene cyanol FF). The samples were incubated at
90 C for 5min prior to electrophoresis on a 20% poly-
acrylamide and 7M urea gel. The images were acquired by
a Typhoon Scanner (GE Healthcare).
Assay for toxin growth inhibition
A TetR-controlled expression system was used to analyze
the effects of Rv1495 or its mutant genes on the growth of
M. smegmatis mc
2 155 (28). Wild-type or mutant Rv1495
genes were cloned into pMind (29) to produce correspond-
ing recombinant plasmids which were then transformed
into M. smegmatis. The strain containing the empty
pMind plasmid was used as negative control. For all
assays, tetracycline was used to induce gene expression
(30). The growth of the recombinant mycobacterial
strains was examined in the presence (induction) or
absence (no induction) of tetracycline (Tc). Cells were
grown at 37 C with aeration in 7H9-Kan-Tw (7H9
medium supplemented with 0.5% Tween 80, 30mg/ml
kanamycin and 0.2% glycerol) to an OD600 of 1.5–2.0.
Cells were diluted in 7H9 medium to an OD600 of 0.2
and grown at 37 C at 200rpm for a further 2h. Aliquots
were taken at the indicated times, and the OD600 was
measured. Each analysis was performed in triplicate.
Representative growth curves were plotted.
Co-IP assays
The in vivo interactions between Rv1495 and MsmTopA
were analyzed by Co-IP according to previously published
procedures with some modiﬁcations (20). Exponentially
growing cells of M. smegmatis with recombinant plasmid
pMind-Rv1495 were harvested, resuspended and lysed in
4ml of buffer [50mM Tris–HCl (pH 7.5), 150mM NaCl,
1mM EDTA, 0.5% Nonidet P-40]. Co-IPs were per-
formed by incubating and shaking 10mg of mycobacterial
cell extract with 3ml of MsmTopA antiserum in 100ml
buffer for 3h at 4 C. A 20-ml slurry of protein A
Sepharose was added, and incubation was continued for
another hour. Immune complexes were collected, and the
beads were washed with the same buffer. Finally, the
beads were resuspended in SDS–PAGE sample buffer.
After boiling, the samples were analyzed by western
blotting using anti-Rv1495 antibody.
Cleavage of synthetic RNA by Rv1495
Oligoribonucleotides (11 bases in length) were commer-
cially synthesized and 50-labeled with [g-
32P]ATP using
T4 polynucleotide kinase. Endoribonuclease activity was
assayed in 10ml of the reaction mixture containing 1–5ml
of Rv1495 and
32P-labeled oligonucleotides in 10mM
Tris–HCl (pH 7.8) (3). Reactions were carried out at
37 C for 30min and stopped by the addition 10mlo f
loading buffer (95% formamide, 20mM EDTA, 0.05%
bromphenol blue). The reaction mixtures were then sub-
jected to 20% denaturing PAGE electrophoresis followed
by autoradiography.
RESULTS
Rv1495 physically interacts with MtbTopA
To uncover the new and as yet unknown cellular effects of
the M. tuberculosis MazF genes, we conducted a screening
using a bacterial two-hybrid assay to isolate proteins
that interact with Rv1495, a MazF homolog. As
shown in Figure 1A, the co-transformants containing
Rv1495/MtbTopA grew well on the screening medium
(Rv3646 encodes the topoisomerase I (MtbTopA) in the
M. tuberculosis genome). Positive co-transformants (CK
+)
grew on the medium, whereas negative co-transformants
(CK
 ) were incapable of growth on the same screening
medium (Figure 1A). No growth was observed for their
self-activated controls, or for their co-transformants ex-
pressing anon-speciﬁcprotein, Rv0054, which could
form polymers with itself. A clear interaction between
Rv0054 with itself was detected (Figure 1A). These
results show that the selective system presented here
worked well and that Rv1495 was found to interact with
the M. tuberculosis TopA.
Further conﬁrmation of this phenomenon was obtained
by observing direct physical interaction between Rv1495
and MtbTopA through a GST pull-down assay. As shown
in Figure 1B, GST-Rv1495 and His-tagged MtbTopA
proteins were co-puriﬁed. One predicted size of His-
tagged MtbTopA protein could be readily pulled down
by GST-Rv1495, which was further conﬁrmed by a
western blotting assay (Figure 1B, lower panel, lane 2).
Co-incubation of GST with His-tagged MtbTopA did
not produce any speciﬁc bands (Figure 1B, lane 3).
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The physical interactions between Rv1495 and MtbTopA
suggested that the MazF protein was in some way
regulating the activities of the MtbTopA topoisomerase.
As shown in Figure 2, addition of increasing amounts of
MtbTopA (0.05–0.15mM) to a reaction mixture contain-
ing plasmid pBluescript as a DNA substrate resulted in a
progressive disappearance of the supercoiled plasmid
DNA band, concomitant with the appearance of a
relaxed plasmid band on the gel (Figure 2A). This con-
ﬁrmed that the MtbTopA could relax supercoiling of this
DNA substrate. This activity was again examined in the
presence of Rv1495 under similar conditions. As shown in
Figure 2, when the concentration of MtbTopA was kept
constant (0.125mM), the amount of supercoiled plasmid
steadily increased with increasing additions of Rv1495
(Figure 2B). In contrast, heat-denatured Rv1495
(Figure 2C) or GST protein (Figure 2D) had no effect
on supercoiling relaxation activity of MtbTopA. The in-
hibitory effect was stronger if MtbTopA was preincubated
with Rv1495 (Supplementary Figure S1). In further
experiments, Rv1495 was found to form a protein
complex with its antitoxin, Rv1494 (Supplementary
Figure S2A and B), but the antitoxin could not block or
reverse the effect of Rv1495 on the MtbTopA activity
(Supplementary Figure S2C).
A previous report showed that Lsr2 inhibited the
activity of MtbTopA through its double-stranded DNA-
binding ability (24). However, DNA-binding assays using
pBluescript plasmid showed no similar activity for Rv1495
(Figure 2E, lanes 2–5), but conﬁrmed this activity for Lsr2
(Figure 2E, lane 7–9). When Rv0054 was used as a
negative control, no double-stranded DNA-binding
activity was observed (Figure 2E, lanes 11–13).
Rv1495 inhibits single-stranded DNA cleavage
by MtbTopA
The function of the topoisomerase I depends on its
binding to single-stranded DNA and subsequent
cleavage activities (18,27). The mechanism underlying
Figure 1. Physical interactions of Rv1495 with MtbTopA. (A) Bacterial two-hybrid assays (Stratagene) for the interaction of Rv1495 with
MtbTopA, which were performed as described under ‘Materials and Methods’ section. Left panel, plate minus streptomycin (str) and 5mM
3-amino-1,2,4-triazole (3-AT), Middle panel, plate plus str and 5mM 3AT. Right panel, an outline of the plates. CK
+, co-transformant containing
pBT-LGF2 and pTRG-Gal11P as a positive control. CK
 , co-transformant containing pBT and pTRG as a negative control. (B) Pull-down assays
for examining the interaction between Rv1495 and MtbTopA. Equimolar amounts of 6  His-MtbTopA combined with GST-Rv1495 were used for
pull-down assays as described in the ‘Materials and Methods’ section. GST was used as the negative control. One predicted size of his-tagged
MtbTopA protein, pulled down by GST-tagged Rv1495 protein, was further examined by a western blotting assay.
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analyzed by exploring the cleavage activity of MtbTopA.
As shown in Figure 3A, a DNA-binding activity on the
32-mer single-stranded DNA substrate was demonstrated
with a positive control, Rv0054 (MtbSSB) (Figure 3A,
right panel, lanes 7–8). No DNA-binding activity was
seen with Rv1495, even at a high protein concentration
(0.96mM) (Figure 3A, right panel, lane 2–5). However, a
substantial shifted protein–DNA complex band, indicative
of DNA-binding, was observed on the gel when an
increasing concentration of MtbTopA (0.06–0.24mM)
was added to the reaction mixture (Figure 3A, left
panel). This conﬁrmed that the MtbTopA had a good
DNA-binding activity with this substrate. A complicated
effect was observed with Rv1495 on the DNA-binding
activity of MtbTopA (Supplementary Figure S3).
The cleavage activity of MtbTopA was further
characterized. As shown in Figure 3B (left panel), a
stepwise increase in amounts of smaller DNA fragment
(19-mer) was observed as 0.1–0.4mM MtbTopA was
added to the reaction mixture. When the concentration
of MtbTopA was kept constant, the cleavage products
steadily decreased in response to addition of increasing
amounts of Rv1495 (3–9mM) (Figure 3B, right panel),
which indicated that Rv1495 inhibited the cleavage
activity of MtbTopA. No effect was observed when
either a heat-denatured Rv1495 protein or an unrelated
protein, GST, was added (Figure 3C).
MtbTopA inhibits mRNA cleavage by Rv1495
We characterized the effect of MtbTopA on the previously
reported mRNA cleavage activity of Rv1495 (10). As
shown in Figure 4A, when an increasing concentration
of Rv1495 (0.5–2.0mM) was added into the reaction
mixture, the levels of the 11-mer mRNA substrate pro-
gressively decreased, with concomitant appearance of a
Figure 2. Effects of Rv1495 on topoisomerase activities of MtbTopA. Topoisomerase activity assays were performed as described under ‘Materials
and Methods’ section. The plasmid pBluscript was used as DNA substrate in all reaction mixtures. The reaction was treated with 6% SDS and 4mg/
ml proteinase K analyzed on a 0.8% agarose gel and then stained with ethidium bromide. Lanes 1, no topoisomerase as negative control. L,
linearized plasmid; R, relaxed plasmid; S, supercoiled plasmid. (A) Different amounts of topoisomerase I (0–0.15mM) were added to 200ng of
supercoiled pBluscript DNA. (B) Effects of different amounts of Rv1495 (0–6mM) on the topoisomerase I (0.125mM) activities on the supercoiled
pBluscript DNA. (C) Effects of different amounts of heated-Rv1495 on the topoisomerase I activities. (D) Effects of different amounts of GST on the
topoisomerase I activities. (E) EMSA assays for the plasmid DNA-binding activities of RV1495, Lsr2, or Rv0054. Lsr2 is a positive control. Rv0054
(MtbSSB) is a negative control.
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lanes 2–5), consistent with mRNA cleavage. When the
concentration of Rv1495 was kept constant (0.75mM),
the level of cleavage products steadily decreased as
MtbTopA content was increased (Figure 4A, middle
panel, lanes 4–6), conﬁrming that the MtbTopA inhibited
the mRNA cleavage activity of Rv1495. In contrast,
Rv0054, used as a negative control, had no inhibitory
effect on cleavage (Figure 4A, right panel, lanes 4–6).
The inhibitory domain of MtbTopA was further
characterized by purifying the NTD of MtbTopA, and
its CTD (Figure 4B). The interactions of these two
domains with Rv1495 were then characterized by a bac-
terial two-hybrid assay. As shown in Figure 4B, CTD
interacted with Rv1495, while NTD did not. CTD also
showed an equivalent inhibitory effect on the mRNA
cleavage by Rv1495 as was seen with the wild-type
MtbTopA (Figure 4C, lanes 2–5). No signiﬁcant effect
was observed for the NTD protein under similar
reaction conditions (Figure 4C, lanes 9–12).
Therefore, the mRNA cleavage activity of Rv1495 was
inhibited through the CTD of MtbTopA.
Rv1495 interacts with M. smegmatis topoisomerase I
(MsmTopA) both in vitro and in vivo
Mycobacterium smegmatis also contains an ortholog of
the M. tuberculosis H37Rv topoisomerase I, MsmTopA
(17). To detect if the interaction is conserved in both
mycobacterial strains, we examined the interaction
between Rv1495 with the M. smegmatis MsmTopA
using a bacterial two-hybrid assay. As shown in
Figure 5A, the co-transformant with Rv1495 and
MsmTopA genes obtained a similar growth on the select-
ive medium to that seen with the Rv1495 and MtbTopA
cotransformant. No growth was observed for several
negative controls (Figure 5A). This indicated that
Figure 3. Effects of Rv1495 on the single-stranded DNA cleavage activity of MtbTopA. 50-end-labeled 32-mer oligonucleotide
(50-CAGTGAGCGAGCTTCCGCTTGACATCCC AATA-30) (27) was used as a speciﬁc single-stranded DNA substrate. DNA-binding and
cleavage assays of MtbTopA were performed as described under ‘Materials and Methods’ section. (A) DNA-binding activity assays for
MtbTopA, Rv1495 and Rv0054 (a positive control). The protein concentrations were indicated on top of the panels. (B) ssDNA cleavage assays
for MtbtopA (left panel) and the effects of Rv1495 (right panel). The 32-mer substrates and 19-mer cleavage products were indicated by arrows. (C)
The effects of the denatured Rv1495 protein (left panel) or GST (right panel) on the cleavage activity of MtbTopA.
8224 Nucleic Acids Research, 2010,Vol.38, No. 22M. tuberculosis Rv1495 might interact with MsmTopA.
Further conﬁrmation of the conserved interaction was
obtained by conducting a GST pull-down assay. As
shown in Figure 5B, GST-Rv1495 and His-tagged
MsmTopA proteins were co-puriﬁed. A protein of the
predicted size of the His-tagged MsmTopA protein
could be readily pulled down by GST-Rv1495, which
was conﬁrmed by a further western blotting assay
(Figure 5B lower panel, lane 2). GST co-incubated with
his-tagged MtbTopA did not produce any speciﬁc bands
(Figure 5B, lane 3).
For further investigation of the physiological signiﬁ-
cance of these in vitro reactions, we examined
co-immunoprecipitation of the MsmTopA with Rv1495,
which was expressed through a pMind recombinant
plasmid in M. smegmatis (29). As shown in Figure 5C,
the speciﬁc hybridization signal for the expressed
Rv1495 in M. smegmatis cell extracts was detected by
anti-Rv1495 antibody (lane 1). Using Protein A beads
that were ﬁrst conjugated with antibody raised against
MsmTopA, an in vivo physical interaction between
MsmTopA and Rv1495 was tested. MsmTopA was
shown to associate with Rv1495 in vivo because an
obvious and a speciﬁc hybridization signal was detected
(Figure 5C, lane 2), although to a lesser extent than the
signal for the expressed Rv1495 in M. smegmatis cell
Figure 4. Effects of MtbTopA on mRNA cleavage activities of Rv1495. (A) mRNA cleavage experiments were performed as described under
‘Materials and Methods’ section. A variant concentration of Rv1495 (0.5–2.0mM) or MtbTopA (40–120nM) proteins was incubated with 0.5mM
mRNA substrates in the reactions. The mRNA substrate, products and their sequences were indicated by arrows. Rv0054 was used a negative
control. (B) Two mutant proteins of MtbTopA and their interactions with Rv1495. The names given to mutants (NTD and CTD) and their amino
acid regions are indicated. Bacterial two-hybrid assays for all mutants were performed as described under ‘Materials and Methods’ section. +
represents growth on the screening plate;   represents no growth on the screening plate. (C) Effects of N-terminal and C-terminal mutant proteins of
MtbTopA on the mRNA cleavage activities of Rv1495. The protein concentrations were indicated on top of the panel.
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speciﬁc signal was detected for the association if the
anti-MsmTopA antibody was absent from the reactions
(Figure 5C, lane 3). Therefore, M. tuberculosis Rv1495
could interact with the homolog of M. smegmatis topo-
isomerase I both in vitro and in vivo.
Characterization of an inhibitory peptide fragment
from Rv1495
To map the interactive domain of Rv1495 with MtbTopA,
we produced several mutant fragments of the Rv1495 gene
(Figure 6A). Using bacterial two-hybrid assays, we found
that the N-terminal 56 amino acid fragment of Rv1495
interacted with MtbTopA (Figure 6A, right panel). We
designed and synthesized two shorter peptides, Rv1495-
N28 and Rv1495-N(29-56), as shown in Figure 6B, and
tested these for inhibitory action on MtbTopA activity.
Rv1495-N(29-56) retained an inhibitory effect on the
topoisomerase I activity (Figure 6C, lower right panel).
Rv1495-N(29-56) loses the mRNA cleavage activity but
retains its ability to inhibit MsmTopA activity and
mycobacterial growth
As shown in Figure 6, Rv1495-N(29-56) retained its ability
to interact with MtbTopA and to inhibit topoisomerase
activity. We compared the effects of two proteins, Rv1495
Figure 5. Interactions of Rv1495 with MsmTopA in vitro and in vivo.( A) Bacterial two-hybrid assays (Stratagene). Experiments were performed as
described under ‘Materials and Methods’ section. Left panel, plate minus streptomycin (str) and 5mM 3-amino-1,2,4-triazole (3-AT), Middle panel,
plate plus str and 5mM 3AT. Right panel, an outline of the plates. (B) Pull-down assays for examining the interaction between Rv1495 and
MsmTopA. Equimolar amounts of 6  His-MsmTopA combined with GST-Rv1495 were used for pull-down assays as described in the ‘Materials
and Methods’ section. GST was used as the negative control. One predicted size of his-tagged MsmTopA protein, pulled down by GST-tagged
Rv1495 protein, was further examined by a western blotting assay. (C) Co-IP assays. Exponentially growing cells of the recombinant M. smegmatis
containing Rv1495-expression plasmid were harvested, resuspended and lysed. Co-IPs were performed by incubating 10mlo fM. smegmatis cell
extracts with 3ml of MsmTopA antiserum for 3h at 4 C. A 20-ml slurry of protein A Sepharose was added, and incubation was continued for
another hour. Immune complexes were collected, and the beads were washed with buffer. Finally, the beads were resuspended in SDS–PAGE sample
buffer. After boiling, the samples were analyzed by western blotting using anti-Rv1495 antibody.
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MsmTopA. As shown in Figure 7A, the activity of
MsmTopA was progressively inhibited as the Rv1495 con-
centration was increased, as indicated by the appearance
of increasing amounts of supercoiled DNA. Similarly, an
inhibition on the function of MsmTopA was also observed
in the presence of Rv1495-N(29-56) (Figure 7A, right
panel).
A further activity assay indicated that Rv1495-N(29-56)
lost its mRNA cleavage ability (Figure 7B, lanes 5–9). In
contrast, the wild-type protein (Rv1495) demonstrated
good activity as increasingly shorter mRNA excision
products were observed on the gel as the Rv1495 concen-
trations were increased stepwise (Figure 7B, lanes 1–4).
Addition of Rv1495 also had clear effects on the myco-
bacterial growth, as indicated by an obvious inhibition
following induction of Rv1495 expression by tetracycline
in M. smegmatis through the pMind recombinant plasmid
(Figure 7C, middle panel). An important observation was
that Rv1495-N(29-56), although lacking mRNA cleavage
activity, was still clearly able to inhibit the growth of
M. smegmatis (Figure 7C, right panel). This growth inhib-
ition could be rescued by coexpression of the C-terminus
of MtbTopA (Supplementary Figure S4). In contrast, the
recombinant strain with the pMind alone showed only a
slight effect on growth (Figure 7C, left panel). In further
experiments, no signiﬁcant effect was observed on the
growth of E. coli following induction of Rv1495 expres-
sion (Supplementary Figure S5). This lack of effect is most
likely because there is no homology between the
C-terminus of Mycobacterium and the E. coli TopA
enzymes. Therefore, Rv1495 or its N-terminal truncation
could negatively regulate the topoisomerase activity of
MsmTopA and inhibit mycobacterial growth.
DISCUSSION
In this study, we have shown that a MazF homolog,
Rv1495, from M. tuberculosis could physically interact
with TopA and that this interaction resulted in mutual
Figure 6. N-terminus of Rv1495 regulates the topoisomerase activities of MtbTopA. Topoisomerase activity and bacterial two-hybrid assays for all
mutants were performed as described under ‘Materials and Methods’ section.+represents growth on the screening plate;   represents no growth on
the screening plate. (A) The N-terminal mutant fragments of Rv1495 containing 56 and 28 amino acid residues (left panel) and their interactions with
MtbTopA assayed by the bacterial two-hybrid system (right panel). (B) Two synthesized short peptides and their amino acid sequences. (C) Effect of
different amount of Rv1495-N28, Rv1495-N56, and Rv1495-N(29-56) (0–6.0mM) on topoisomerase activity.
Nucleic Acids Research, 2010,Vol.38, No. 22 8227inhibition of the respective activities of both proteins.
Rv1495 physically interacted with MsmTopA, both
in vitro and in vivo, and inhibited mycobacterial growth
when expressed in M. smegmatis. An N-terminal fragment
of Rv1495 was further characterized and shown to retain
the capacity for both physical interaction with, and inhib-
ition of, TopA, even though it had lost its mRNA cleavage
activity. Therefore, in addition to its known RNA
interferase function, the bacterial MazF protein also can
directly interact with and modulate the activities of topo-
isomerase I. This suggests an additional regulatory
function of the M. tuberculosis MazEF system on bacterial
growth that functions separately from its ribonuclease
activity.
The MazEF system may be involved in ability of
M. tuberculosis to undergo long-term dormancy in
human tissues, which is essential for the persistence of
the pathogen (31,32). The activity of the sole TopA in
this species with respect to relaxation of negative super-
coiling might be important during stress responses, since a
number of stress genes have to be induced for survival
(3,33). In the current study, we found that the function
Figure 7. Activities of Rv1494 and Rv1495-N(29-56) and their effects on the mycobacterial growth. (A) Effects of Rv1495 and Rv1495-N(29-56) on
the topoisomerase activities of MsmTopA. The assays were performed as described under ‘Materials and Methods’ section. L, linearized plasmid; R,
relaxed plasmid; S, supercoiled plasmid. The protein concentrations were indicated on top of the panels. (B) mRNA cleavage activity assays.
Experiments were performed as described under ‘Materials and Methods’ section. A varying concentration of Rv1495 or Rv1495-N(29-56)
proteins was incubated with 0.5mM mRNA substrates in the reactions. The mRNA substrate and products were indicated by arrows. (C) Effects
of the expressions of Rv1495 and Rv1495-N(29-56) on the mycobacterial growth. A TetR-controlled expression system was used to analyze the
effects of Rv1495 genes on the growth of M. smegmatis mc
2 155 as described in the ‘Materials and Methods’ section. The growth of these
recombinant mycobacterial strains were examined in the presence (induction) or absence (no induction) of tetracycline (Tc). Aliquots were taken
at the indicated times and the OD600 was measured. Each analysis was performed in triplicate. The representative growth curves were plotted. The
recombinant mycobacterial strains were indicated above the panels.
8228 Nucleic Acids Research, 2010,Vol.38, No. 22of Rv1495, a toxin protein, was linked to the topoisomer-
ase I of the pathogen. Mycobacterium tuberculosis might
have evolved a mechanism for survival within its host
macrophage cells that operates by perfectly balancing
the interactions of a pair of MazEF and the interactions
of MazEF with the DNA topoisomerase I.
This mechanism would allow the organism to become
dormant within the hostile environment of human macro-
phage cells. For example, MazE and MazF would
normally form a stable complex, which would prevent
RNA cleavage by MazF. When the pathogen confronts
the stressful environment within human cells, MazE
would be degraded by the ATP-dependent ClpPA serine
protease (1). This would result in the release of MazF
from the MazE–MazF protein complex. As shown
earlier (3,16), MazF, on the one hand, could cleave
mRNA and inhibit gene expression. On the other hand,
as shown in the current study, MazF could inhibit the
activity of topoisomerase I through a direct protein–
protein interaction, again inhibiting gene expression.
These two mechanisms would then contribute to
pathogen dormancy.
The importance of TA systems in the life cycle of
M. tuberculosis is suggested by the presence of the remark-
ably large number of these genes (15). In contrast, despite
a much larger genome (7 versus 4.4Mb) M. smegmatis has
only two TA systems (2,34), including one MazF
homolog. However, although M. tuberculosis and
M. smegmatis have multiple groups of MazEF systems,
both of their genomes encode a single highly homologous
type I topoisomerase. Interestingly, in the current study,
we found that Rv1495 interaction was conserved between
both MtbTopA and MsmTopA and that it had a similar
inhibitory action on topoisomerase activity of both organ-
isms. An in vivo interaction between Rv1495 and the
MsmTopA of M. smegmatis was also demonstrated.
Thus, this interaction between these two proteins might
have physiological importance in M. tuberculosis.
Mycobacterium smegmatis has been used as a suitable
host for the TA growth assays since it contains only two
TA systems (2,34). In the current study, we observed that
Rv1495 could inhibit the growth of M. smegmatis when
Rv1495 was expressed through a pMind recombinant
plasmid. Importantly, an N-terminal fragment of
Rv1495, Rv1495-N(29-56), was also effective at inhibiting
mycobacterial growth (Figure 7C), although it was less
effective than the full-length Rv1495 (Figure 7A). Since
Rv1495-N(29-56) had lost its mRNA cleavage activity,
growth inhibition is most likely attributable to the
effects of the MazF protein on the functioning of the topo-
isomerase (Figure 7B). Therefore, two different mechan-
isms would appear to contribute to the inhibition of
mycobacterial growth by Rv1495. On the one hand, its
interferase activity would cleave mRNA. On the other
hand, its physical interaction with TopA would negatively
regulate the relaxation of supercoiled DNA carried out by
the topoisomerase.
The incidence of tuberculosis has been increasing sub-
stantially on a worldwide basis over the past decade. To
complicate matters, drug-resistant TB has also become
a major public health concern. However, no new
tuberculosis-speciﬁc drugs have been discovered for
more than 40 years. Bacterial topoisomerase I is
required for preventing hypernegative supercoiling of
DNA during transcription (35), which has been con-
sidered to be especially important for the pathogenic
adaptation to stressful environments (33,36). The
genome of M. tuberculosis encodes a type I topoisomerase,
but all attempts to isolate a transposon insertion mutant
in the topA of M. tuberculosis gene have been unsuccessful
(20). This suggests that M. tuberculosis topoisomerase I is
critical for survival. Recent studies have found that inter-
ference with the function of topoisomerase I and stabiliza-
tion of its covalent complex with cleaved DNA can lead to
bacterial cell death (37–39). Thus, topoisomerase I of
pathogens is now becoming recognized as a promising
new target for combating bacterial drug-resistance. In
the current study, we characterized a N-terminal
fragment, Rv1495-N(29-56), which retained the inter-
action with TopA and the inhibitory activity on the topo-
isomerase function. These speciﬁc protein–protein and
protein–peptide interactions provided us with important
clues for developing effective antibiotics that could target
TB topoisomerase I. Compounds that activate or mimic
bacterial toxins could quite feasibly be developed into
novel antibiotics. On the one hand, drugs of this type
would promote pathogenic programmed cell death by pre-
venting or reducing the association between a given
MazEF pair. On the other hand, they would also
promote an inhibition of the function of the topoisomer-
ase I and thus interfere with transcriptional regulation.
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